Building on these promising outcomes, we subsequently conducted a single-arm, open-label, multicenter study to assess the efficacy of tranilast as an additional therapy for patients with MD and heart failure, with BNP levels > 100 pg/mL during standard cardiac protection therapy [12]. Here, NPPB is linked to heart failure.